"Onco360 is grateful for the opportunity to partner on another therapy with the team at SpringWorks Therapeutics and become a ...

Achieved $61.5 million and $172.0 million in fourth quarter and full year 2024 OGSIVEO® (nirogacestat) U.S. net product revenues, respectively ...

“We are proud to add GOMEKLI for the treatment of neurofibromatosis type 1 patients to our growing portfolio of rare disease therapies.” Mirdametinib is a MEK1/2 inhibitor now approved in the ...

The FDA has approved an oral, small molecule MEK inhibitor for adult and pediatric patients 2 years of age and older with ...

SWTX reports mixed fourth-quarter 2024 results. Its newly approved desmoid tumor drug, Ogsiveo, witnesses a strong launch.

We developed and are commercializing OGSIVEO® (nirogacestat) as the first and only FDA-approved medicine for adults with desmoid tumors and GOMEKLI™ (mirdametinib) as the first and only ...

the potential for GOMEKLI to become an important new treatment for patients with NF1-PN, our expectations regarding the timing and results of the EMA’s review of our MAA for mirdametinib and our ...